228401-39-6

Upstream product

• 51834-97-0 6-methoxypyridine-3-ol 
• 350-46-9 4-Fluoronitrobenzene 
• 7646-69-7 sodium hydride 
• 624-28-2 2,5-dibromopyridine 
• 13472-85-0 2-methoxy-5-bromopyridine 

Relevant academic research and scientific papers

INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS

This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases, other than cancer and proteolytic enzyme mediated diseases, other than cancer, and pharmaceutical compositions for use in such therapy.

Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas

This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS

Methods of treating tumors mediated by raf kinase, with substituted urea compounds, and such compounds per se.

INHIBITION OF p38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS

This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases and proteolytic enzyme mediated diseases, and pharmaceutical compositions for use in such therapy.

Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas

This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases and proteolytic enzyme mediated diseases, and pharmaceutical compositions for use in such therapy.

Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas

This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

INHIBITION OF RAF KINASE USING QUINOLYL, ISOQUINOLYL OR PYRIDYL UREAS

This invention relates to a group of quinolyl, isoquinolyl and pyridyl ureas, their the use in treating raf mediated diseases, and pharmaceutical compositions which contain these ureas for use in such therapy.

Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors

This invention relates to the use of a group of heteroaryl ureas containing nitrogen in treating p38 mediated diseases, and pharmaceutical compositions for use in such therapy.